

DAFTAR PUSTAKA

- Antonarakis, S.E., 1998. Recommendations for a nomenclature system for human gene mutations. *Hum Mutat*, 11: 1-3.
- Au, W.Y., Caguioa, P.B., Chuah, C., Hsu, S.C., Jootar, S., Kim, D.-W., *et al.*, 2009. Chronic myeloid leukemia in Asia. *Int J Hematol*, 89: 14-23.
- Baccarani, M. dan Dreyling, M., 2010. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 21(5 suppl): v165-v167.
- Bagg, A., 2002. Chronic Myeloid Leukemia, A minimalistic view of post-therapeutic monitoring. *J Mol Diagn*, 4(1): 1-10.
- Bennour, A., Ouahchi, I., Achour, B., Zaier, M., Youssef, Y.B., Khelif, A., *et al.*, 2013. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. *Med Oncol*, 30(348): 1-6.
- Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J.M. & Melo, J.V., 1998. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. *Blood*, 92(9): 3362-3367.
- Burmeister, T. dan Reinhardt, R., 2008. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. *Leuk Res*, 32: 579-585.
- Burmeister, T., Schwartz, S., Taubald, A., Jost, E., Lipp, T., Schneller, F., *et al.*, 2007. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. *Haematologica*, 92(12): 1699-1702.
- Calabretta, B. dan Perrotti, D., 2004. The biology of CML blast crisis. *Blood*, 103(11): 4010-4022.
- Chasseriau, J., Rivet, J., Bilan, F., Chomel, J.-C., Guilhot, F., Bourmeyster, N., *et al.*, 2004. Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR. *J Mol Diagn*, 6(4): 343-347.
- Clarkson, B., Strife, A., Wisniewski, D., Lambek, C. dan Liu, C., 2003. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. *Leukemia*, 17: 1211-1262.
- Cortes, J.E., Talpaz, M., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., *et al.*, 2006. Staging of chronic myeloid leukemia in the imatinib era : An evaluation of the World Health Organization proposal. *Cancer*, 106(6): 1306-1315.
- de Rozas A.M, P., Gonzales J., Aloy N., dan Badiola I., 2008. Standardization of nested-PCR for the detection of *Pasteurella Multocida*, *Staphylococcus*

- aureus, Myxomatosis Virus, And Rabbit Haemorrhagic Disease Virus. In *9th World Rabbit Congress*; June 10-13, pp:1035-1039. Verona, Italy.
- De V. Meissner, R., Dias, P.M.B., Covas, D.T., Job, F., Leite, M. dan Nardi, N.B., 1998. A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients. *Br J Haematol*, 103: 224–226.
- Druker, B.J., 2008. Translation of the Philadelphia chromosome into therapy for CML. *Blood*, 112(13): 4808-4817.
- Elias, M.H., Baba, A.A., Azlan, H., Rosline, H., Sim, G.A., Padmini, M., *et al.*, 2014. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome. *Leuk Res*, 38: 454-459.
- Elmaagacli, A.H., Beelen, D.W., Opalka, B., Seeber, S. dan Schaefer, U.W., 2000. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates. *Ann Hematol*, 79: 424–431.
- Elnifro, E.M., Ashshi, A.M. & Cooper, R.J., 2000. Multiplex PCR: optimization and application in diagnostic Virology. *Clin.Microbiol.Rev*, 13(4): 559-570.
- Fausel, C., 2007. Targeted chronic myeloid leukemia therapy: seeking a Cure. *J Manag Care Pharm*, 13 Suppl: S8-S12.
- Frazer, R., Irvine, A.E. & McMullin, M.F., 2007. Chronic myeloid leukaemia in the 21st century. *Ulster Med J*, 76(1): 8-17.
- Frederick, L., Beardell, F. dan Viswanatha, D.S., 2014. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm. *Hum Pathol*, p : 21-26.
- Garcia-Manero, G., Faderl, S., O'Brien, S., Cortes, J., Talpaz, M. dan Kantarjian, H.M., 2003. Chronic myelogenous leukemia: a review and update of therapeutic strategies. *Cancer*, 98(3): 437-457.
- Goh, H.-G., Hwang, J.-Y., Kim, S.-H., Lee, Y.-H., Kim, Y.-L. dan Kim, D.-W., 2006. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. *Transl Res*, 148(5): 249-256.
- Hantschel, O. dan Superti-Furga, G., 2004. Regulation of the c-ABL and BCR-ABL tyrosine kinases. *Mol Cell Bio*, 5: 33-44.
- Haznedaroğlu, İ.C., 2013. Current management of chronic myeloid leukemia with tyrosine kinase inhibitors. *Turk J Hematol*, 30: 247-255.

- Henegariu, O., Heerema, N.A., Dlouhy, S.R., Vance, G.H. dan Vogt, P.H., 1997. Multiplex PCR: Critical parameters and step by step protocols. *BioTechniques*, 23: 504-511.
- Irshad, S., Butt, M.A. dan Joyia, A., 2012. Frequency of different BCR-ABL fusion transcripts in chronic myelogenous leukemia patients in Pakistan. *IJAVMS*, 6(6): 418-423.
- Jabbour, E.J. dan Kanterjian, H., 2014. CME Information: chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. *Am J Hematol*, 89(5): 547-556.
- Kim, D.-W., Banavali, S.D., Bunworasate, U., Goh, Y.-T., Ganly, P., Huang, H., *et al.*, 2010. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. *Leuk Res*, 34: 1459-1471.
- Laurent, E., Talpaz, M., Kantarjian, H. dan Kurzrock, R., 2001. The BCR gene and Philadelphia chromosome-positive leukemogenesis. *Cancer Res*, 61: 2343–2355.
- Loffert, D., Karger, S., Twieling, G., Ulber, V. & Kang, J., 1999. Optimization of multiplex PCR. *Qiagen News*, (2) : 5-8.
- Lu, X., Song, X., Ye, Y., Liu, X., Zhou, Y., Zhang, L., *et al.*, 2011. Quantitative detection of BCR–ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment. *Mol Biol Rep*, 38: 3101–3105.
- Markoulatos, P., Siafakas, N. dan Moncany, M., 2002. Multiplex polymerase chain reaction: a practical approach. *J Clin Lab Anal*, 16: 47-51.
- Mondal, J.D., Tewary, D. dan Sardar, S.M., 2014. Chronic myeloid leukemia – An overview. *Int J Sci Res*, 3(1): 128-132.
- Ohsaka, A., Shiina, S., Kobayashi, M., Kudo, H. dan Kawaguchi, R., 2002. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190^{BCR-ABL}. *Intern Med*, 41(12): 1143-1187.
- Pane, F., Intrieri, M., Quintarelli, C., Izzo, B., Muccioli, G.C. dan Salvatore, F., 2002. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. *Oncogene*, 21: 8652 – 8667.
- Panjarian, S., Iacob, R.E., Chen, S., Engen, J.R. dan Smithgall, T.E., 2013. Structure and dynamic regulation of Abl kinases. *J. Biol. Chem*, 1-11.
- Perrotti, D., Jamieson, C., Goldman, J. dan Skorski, T., 2010. Chronic myeloid leukemia: mechanisms of blastic transformation. *J Clin Invest.*, 120 (7): 2254-2264.
- Quintas-Cardama, A. dan Cortes, J., 2009. Molecular biology of BCR-ABL1–positive chronic myeloid leukemia. *Blood*, 113(8): 1619-1630.

- Ren, R., 2002. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. *Oncogene*, 21: 8629 – 8642.
- Roux, K.H., 2009. Optimization and troubleshooting in PCR. *Cold Spring Harb Lab Press*, 4(4): 1-7.
- Rumpold, H. dan Webersinke, G., 2011. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia – is it all BCR-ABL? *Curr Cancer Drug Targets*, 11(1): 3-19.
- Salesse, S. dan Verfaillie, C.M., 2002. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. *Oncogene*, 21: 8547 - 8559.
- Saußeles, S., Weißer, A., Müller, M., Emig, M., La Rosee, P., Paschka, *et al.*, 2000. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. *Leukemia*, 14 : 2006-2010.
- Shet, A., Jahagirdar, B. dan Verfaillie, C., 2002. Chronic myelogenous leukemia: mechanisms underlying disease progression. *Leukemia*, 16: 1402–1411.
- Sillaber, C., Mayerhofer, M., Agis, H., Sagaster, V., Mannhalter, C., Sperr, W.R., *et al.*, 2003. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wien Klin Wochenschr*, 115/13–14: 485-504.
- Smith, D.L., Burthem, J. dan Whetton, A.D., 2003. Molecular pathogenesis of chronic myeloid leukaemia. *Expert Rev Mol Med*, 5: 1-27.
- Valent, P., Lion, T., Wolf, D., Sillaber, C., Agis, H., Petzer, A., *et al.*, 2008. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. *Wien Klin Wochenschr*, 120: 697-709.
- Vardiman, J.W., 2009. Chronic myelogenous leukemia, BCR-ABL1+. *Am J Clin Pathol*, 132: 250-260.
- Wertheim, J.A., Miller, J.P., Xu, L., He, Y. & Pear, W.S., 2002. The biology of chronic myelogenous leukemia: mouse models and cell adhesion. *Oncogene*, (21), 8612 – 8628.
- Wizard SV Gel and PCR Clean-Up System (Editorial). 2010. *Technical Bulletin*, 4-7.
- Yaghmaie, M., Ghaffari, S.H., Ghavamzadeh, A., Alimoghaddam, K., Jahani, M., Mousavi, S.-A., *et al.*, 2008. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. *Arch Iranian Med*, 11(3): 247 – 251.
- Zhang, J.G., Lin, F., Chase, A., Goldman, J.M. dan Cross, N.C.P., 1996. Comparison of genomic DNA and cDNA for detection of residual disease

after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. *Blood*, 87(6): 2588-2593.